Immunomics research uses in silico epitope prediction, as well as in vivo and in vitro approaches. We inoculated BALB/c (H2d) mice with 17DD yellow fever vaccine to investigate the correlations between approaches used for epitope discovery: ELISPOT assays, binding assays, and prediction software. Our results showed a good agreement between ELISPOT and binding assays, which seemed to correlate with the protein immunogenicity. PREDBALB/c prediction software partially agreed with the ELISPOT and binding assay results, but presented low specificity. The use of prediction software to exclude peptides containing no epitopes, followed by high throughput screening of the remaining peptides by ELISPOT, and the use of MHC-biding assays to characterize the MHC restrictions demonstrated to be an efficient strategy. The results allowed the characterization of 2 MHC class I and 17 class II epitopes in the envelope protein of the YF virus in BALB/c (H2d) mice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615555 | PMC |
| http://dx.doi.org/10.1016/j.virol.2008.04.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel H-2D-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.
J Immunother Cancer
October 2024
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Article Synopsis
- Melanoma antigen gene (MAGE)-type antigens are effective targets for cancer immunotherapy, as they appear in cancer cells but not in normal tissues, with the exception of some male germline cells.
- Researchers focused on the mouse P1A antigen, identifying a specific CD8 T-cell epitope presented by the H-2D molecule in C57BL/6 mice, using adenovirus and modified vaccinia Ankara vaccines to enhance immune responses.
- The study successfully induced a strong immune response targeting a specific 9-amino acid peptide from the P1A antigen, leading to protection against specific tumors and the identification of T-cell receptors (TCRs) that could be used for adoptive cell therapy.
Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.
NPJ Vaccines
June 2024
Department of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA, 92697-4800, USA.
It is recommended that the adjuvant Montanide ISA 720 VG be used at a concentration of 70% v/v. At this concentration, Montanide causes at the site of immunization a local granuloma that can last for several weeks. To determine the safety and protective efficacy of a Chlamydia muridarum MOMP vaccine, formulated with CpG-1826 and four different concentrations of Montanide (70%, 50%, 30% and 10%), BALB/c (H-2) female mice were immunized twice intramuscularly.
View Article and Find Full Text PDFValidation of novel conditional ligands and large-scale detection of antigen-specific T cells for H-2D and H-2K.
Sci Rep
May 2024
Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.
The UV-mediated peptide exchange has enabled the generation of multiple different MHC multimer specificities in parallel, surpassing tedious individual refolding of MHC molecules with peptide ligands. Murine models are acknowledged as an effective tool for preclinical research to advance our understanding of immunological mechanisms, with the potential translatability of key learnings from mouse models to the clinic. The common inbred mouse strain BALB/c is frequently used in immunological research.
View Article and Find Full Text PDFSequential Immunizations with Influenza Neuraminidase Protein Followed by Peptide Nanoclusters Induce Heterologous Protection.
Viruses
January 2024
Hunan Provincial Key Laboratory of Medical Virology, College of Biology, Hunan University, Changsha 410082, China.
Enhancing cross-protections against diverse influenza viruses is desired for influenza vaccinations. Neuraminidase (NA)-specific antibody responses have been found to independently correlate with a broader influenza protection spectrum. Here, we report a sequential immunization regimen that includes priming with NA protein followed by boosting with peptide nanoclusters, with which targeted enhancement of antibody responses in BALB/c mice to certain cross-protective B-cell epitopes of NA was achieved.
View Article and Find Full Text PDFAnalyses, Experimental Verification and Application in DNA Vaccines of Ebolavirus GP-Derived pan-MHC-II-Restricted Epitopes.
Vaccines (Basel)
October 2023
Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China.
(1) Background and Purpose: Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), which causes extremely high mortality and widespread epidemics. The only glycoprotein (GP) on the surface of EBOV particles is the key to mediating viral invasion into host cells. DNA vaccines for EBOV are in development, but their effectiveness is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!